Robert DiPaola, Stephen Gruber, and Candace Johnson named to AACI Board of Directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ROBERT DIPAOLA, STEPHEN GRUBER and CANDACE JOHNSON were elected to the board of directors of the Association of American Cancer Institutes. Their three-year terms will begin Oct. 25, during the annual meeting of the AACI and the Cancer Center Administrators Forum in Washington, D.C.

DiPaola is director of the Rutgers Cancer Institute of New Jersey. He has held multiple local and national positions including the founding director and program leader of the Prostate Cancer Center at the Cancer Institute of New Jersey; national chairman of the Genitourinary Committee of the Eastern Oncology Cooperative Group; chief of Medical Oncology at Robert Wood Johnson Medical School; and was appointed as director of the CINJ in 2008.

Gruber was appointed director of the USC Norris Comprehensive Cancer Center in 2011. He is a professor of medicine and preventive medicine, and holds the H. Leslie and Elaine S. Hoffman Cancer Research Chair at the University of Southern California. Prior to his appointment at USC Norris, Gruber was associate director of cancer prevention and control at the University of Michigan Comprehensive Cancer Center.

As president and chief executive officer of Roswell Park Cancer Institute, Johnson oversees all cancer research, patient care, and NCI core funding. Johnson also serves as the Wallace Family Chair in Translational Research and as a professor of oncology. Prior to her appointment, Johnson was deputy director of the institute and also chair of the Department of Pharmacology and Therapeutics for more than a decade.

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login